Study lays groundwork for blood test to aid in the detection and monitoring of myeloma

Only 5 percent of myeloma cases are stage I when diagnosed. One reason may be the lack of good routine screening tests to identify patients who will progress to myeloma. A new study in The Journal of Molecular Diagnostics found that abnormal levels of microRNAs (miRNAs) detected in the bone marrow of multiple myeloma patients may also be detectable in peripheral blood, and their measurement may be a way to both mark myeloma onset and track its progression from earlier asymptomatic stages. —> Read More